Teva R&D Spending Target Raised To 7.5% Of Sales
Executive Summary
Teva Pharmaceuticals will boost research and development spending this year toward a new goal of 7.5 percent of sales, company executives announced during the firm's fourth quarter earnings call Feb. 12